Dr Lal PathLabs Q3 FY26 Earnings Results: Revenue Rises 11% to ₹660 Crore, PAT at ₹91 Crore

Dr Lal PathLabs Limited reported a steady performance for the third quarter of FY26, with consolidated revenue rising 10.6% year-on-year to ₹660 crore, compared with ₹597 crore in the same quarter last year. For the nine-month period ended December 2025, revenue grew 10.8% to ₹2,060 crore.

Dr Lal PathLabs Profitability and Margins

EBITDA before exceptional items increased 16.3% YoY to ₹179 crore, with margins improving to 27.2% from 25.8% last year. However, the company reported an exceptional expense of ₹30.1 crore due to the implementation of new labour codes.

After accounting for this impact, profit before tax (PBT) declined 10.1% YoY to ₹124 crore, while profit after tax (PAT) stood at ₹91 crore, down 6.8% year-on-year. PAT margin for the quarter came in at 13.9%.

9-Month Performance

For the nine months ended December 2025, Dr Lal PathLabs reported:

• EBITDA of ₹596 crore, up 13.1% YoY
• PAT of ₹378 crore, a growth of 12.2% YoY
• EPS of ₹22.4, compared with ₹20.0 last year

Dividend and Balance Sheet Strength

The company announced an interim dividend of ₹3.5 per share for Q3 FY26. As of December 31, 2025, cash and bank balances stood at a healthy ₹1,411 crore, reflecting strong liquidity.

About Dr Lal PathLabs

Dr Lal PathLabs is one of India’s leading diagnostic service providers, offering a wide range of pathology and radiology tests. As of March 31, 2025, the company operated 298 laboratories, over 6,600 patient service centres, and more than 12,000 pick-up points across the country.

Also Read: Adani Power Increases Electricity Export to Bangladesh!

Dr Lal PathLabs Share Price Movement

Dr. Lal PathLabs share price (NSE: LALPATHLAB) was trading at ₹1,401.70 on Friday afternoon, up ₹6.50 or 0.47%. The stock opened at ₹1,390, touched an intraday high of ₹1,413.90 and a low of ₹1,379.20. The company’s market capitalisation stands at ₹23.38 lakh crore, with a P/E ratio of 43.72. Over the past year, the stock has moved between a 52-week high of ₹1,770 and a 52-week low of ₹1,146.78. 

Conclusion

Dr Lal PathLabs delivered stable revenue growth and margin improvement in Q3 FY26, supported by strong operational performance. While profitability was impacted by labour code-related costs, the company’s solid cash position and consistent growth underline its long-term strength in India’s diagnostics sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.